Κατεύθυνση Κλινικές Μελέτες: Σχεδιασμός και Εκτέλεση
Library of the School of Health Sciences

2019-03-07

2019

Vlachothanasi Efthymia

Ζαγουρή Φλώρα, Αναπληρώτρια Καθηγήτρια, Ιατρική Σχολή, ΕΚΠΑ, Eπιβλέπουσα
Καστρίτης Ευστάθιος, Αναπληρωτής Καθηγητής, Ιατρική Σχολή, ΕΚΠΑ
Σταματελόπουλος Κίμων, Αναπληρωτής Καθηγητής, Ιατρική Σχολή, ΕΚΠΑ

Συστηματική ανασκόπηση χορήγησης της απρεπιτάντης σε ασθενείς που λαμβάνουν χημειοθεραπεία με βάση τη σισπλατίνη

Greek

Systematic review of administration of aprepitant in patients treated with cisplatin-based chemotherapy

According to the current MASCC-ESMO guidelines, a combination of a neurokinin-1 receptor (NK1RA), dexamethasone and a 5-HT3 receptor antagonist (5-HT3RA) is recommended to prevent cisplatin induced emesis. We performed a systematic review of randomized clinical trials Phase III (RCTs) that compared aprepitant + dexamethasone + 5-HT3RA versus dexamethasone + 5-HT3RA in patients who received the first cycle of cisplatin-based chemotherapy. The primary outcome was a complete response (CR), defined as non-vomiting and no rescue medication. Seven trials were eligible and complete response data were available from 7 studies (3574 patients).
The addition of aprepitant improves Complete Response in all phases: acute phase, late phase, but also in the total period, 69,92% vs. 52,41%. There was no significant heterogeneity between the clinical trials. In patients receiving cisplatin-based chemotherapy, the addition of NK1RA to dexamethasone and 5-HT3RA is associated with a clinically significant improvement in CR.

Health Sciences

Nausea, Vomiting, Chemotherapy, Cisplatin, NK1 receptor antagonist, Aprepitant, Systemic review, Solid tumor

Yes

1

Yes

31

33

File access is restricted only to the intranet of UoA.

https://pergamos.lib.uoa.gr/uoa/dl/object/2865311